glp-1 comparison agonists vs bariatric surgery weight loss Metabolic and versus glucagon-like peptide-1 receptor agonist therapy: A of cardiovascular outcomes in patients with obesity Bariatric Surgery Yields 5x More – Unlocking The Power of GLP-1

Despite promising findings, the lack of standardized experimental models and inconsistent GLP-1-RA dosing regimens across studies limits direct comparison and reproducibility

In a study of 3,731 patients assigned to take either liraglutide or placebo, 63.2% of patients taking liraglutide lost at least 5% of their body weight and 33.1% of patients lost at least 10% of their body weight

Eng who had strong expertise in RIA for measuring peptides in blood and new methods to isolate peptides and unravel their structures

Lancet (1999) 353(9167):18659

The most common side effects of dulaglutide are nausea, vomiting, and diarrhea

Therapies for inter-relating diabetes and obesity GLP-1 and obesity